OTC:BLEG
Experienced Executive and Advisory Team
Amin Jan
President & CEO
Pharmacist & Clinical Research Coordinator
Prof Sonal Singh, MD
Medical Lead
UMass Professor, Clinician Scientist & Drug Policy Expert
Prof Eran Bendavid, MD
Research Lead
Stanford Professor
Prof Martin Schechter, MD, PhD
Epidemiology Lead
Order of Canada recognized addiction researcher
Dr Kristian Thorlund, MD
Founder
Business Leader, Biostatistician & serial entrepreneur
Dr Scott MacDonald, MD
Addiction Medicine Specialist
Addictions clinic leader, globally recognized researcher
Blake Daly, MBA
Business Development Lead
Led 20+ startups
Addictions are a globally
increasing health crisis
Current treatments are ineffective, expensive
and cannot be accessed by patients
Bio Legacy Evaluative Group has developed technology and assembled world leaders to tackle this
Naloxone Leading the Intranasal Device Market
- The naloxone market is projected to grow from $371M in 2022 to over $1.16B by 2032, with a CAGR of ~11.9%, reflecting consistent and strong demand.
- Despite growing demand, naloxone use is limited by high cost, inconsistent dosage and complex delivery system.
Our Solution
Improve Intranasal Drug Delivery
We have redesigned intranasal naloxone delivery as an all-in-one device to reduce costs, while addressing limitations of current market products.
Improved Manufacturing
Our patented all-in-one device simplifies what is today a complex, multi-part system -reducing cost and operational complexity
Improved Dosing Precision
Enhanced dose precision improves treatment consistency and simplifies prescribing and usage
Innovative New Treatment Options
Our platform enables nasal administration of compounds that conventional intranasal devices could not reliably deliver due to physical, chemical, or manufacturing constraints.
Our Strategy
Additional Markets beyond naloxone
A second device we have invented allows for mixing solutions with lyophilized powder. This opens the new markets including for vaccines and other medications currently inaccessible.
Vaccines
Intranasal delivery would facilitate quicker pandemic response and opens the door to self-use vaccination. This can also help hard-to-reach regions globally who are underserved by vaccination efforts.
Other Cold Chain Medications
Many medications require continuous refrigeration from manufacturing to administration – the “cold chain.” A device to reconstitute at point-of-care could significantly streamline delivery logistics for cold-chain dependent therapies.
Go-to-market Timeline for Naloxone Device
Q3 2025
Begin manufacturing prototyping
Q4 2025
Complete device for full patent submission
Q1 2026
Begin clinical trial to demonstrate non-inferiority
Q2/3 2026
Get readout of clinical trial results
Q4 2026
A Class II medical device requires minimal approval.
Q1 2027
Read to market for Naloxone
Projected Revenue in 3 scenarios of Growth
| Year | Market Size |
Slow Growth (max 10%) |
Avg Growth (max 25%) |
High Growth (max 60%) |
|---|---|---|---|---|
|
Year 1
|
$465M
|
2% = $9.3M
|
5% = $23.3M
|
10% = $46.5M
|
|
Year 2
|
$521M
|
4% = $20.8M
|
10% = $52.1M
|
20% = $104.2M
|
|
Year 3
|
$584M
|
6% = $35.0M
|
15% = $87.6M
|
35% = $204.4M
|
|
Year 4
|
$654M
|
8% = $52.3M
|
20% = $130.8M
|
50% = $327.0M
|
|
Year 5
|
$733M
|
10% = $73.3M
|
25% = $183.3M
|
60% = $439.8M
|
